Teddy bear picnic brings free travel to Welshpool railway
The popular family-themed Teddy Bears Picnic event will take place on July 12 and 13, offering a variety of attractions.
As well as free travel for children accompanied by a fare-paying adult, the event features a Teddy Trail, Ted's Story Time, a chance to meet the railway's own Teddy Bear family, and a Name the Bear competition.
At Llanfair Caereinion, the tearoom, shop, Connections Visitor Centre, and the Cloverlands Model Car Museum will be open.
The museum boasts a collection of more than 8,000 model cars.
The free travel offer is valid on any train service over the weekend.
Return trains will be pulled by the railway's fleet of steam or heritage diesel locomotives.
They depart from Llanfair Caereinion at 10.30am, 12pm, 1.45pm, and 3.30pm, and from Welshpool Raven Square at 11.45am and 1.30pm.
The line is expected to be busy, so travellers and their teddies are encouraged to book in advance.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Once a vaudeville playhouse, the historic Baker Theater in Dover is listed for $3.7M
The term "vaudeville" may make you think of musty old theaters and outdated forms of entertainment. But at one point, it was a thriving outlet for artistic expression. It's where music, dance, theater and comedy became one, completed with the allure of plate spinners, contortionists, mimes and more. North Jersey was home to some of the region's largest vaudeville playhouses during the early 20th century. And while this style of entertainment is a thing of the past, a relic of this bygone era still stands in Morris County — and now it's listed for sale. The historic Baker Theater, located at 39 W Blackwell St. in the heart of downtown Dover, is officially on the market for $3.7 million. The venue was one of North Jersey's most popular spots for vaudeville performances and motion picture screenings during its time. "It's an important part of the Dover community, but it's also a really important part of Morris County and the arts as a whole because of the history behind where it started," said listing agent Mary Dougherty of The Dougherty Group at Compass New Jersey. It all started with local businessman William H. Baker, who originally sold groceries and dry goods out of separate businesses in Dover in the 1870s. Baker broke into the entertainment business in the 1880s by opening the Baker Opera House, a venue specifically designed to house vaudeville acts. The building — which still stands today at 16 W Blackwell St. and is on the National Register of Historic Places — operated for nearly 20 years before it abruptly closed in 1904. Two years later, Baker officially opened the new Baker Theater: A bigger and better entertainment destination just down the street from his original venue. "Baker's involvement in the entertainment business grew to such a degree that his original Opera House became both too small and inadequate for the type of productions often staged there. By 1906, Baker's ambition resulted in the construction of the Baker Theater," the National Register of Historic Places form for the Baker Opera House states, dated 1981. Boasting 1,200 seats, two balconies and a stage big enough to accommodate 500 people, it had the largest seating capacity of any auditorium at the time, according to the National Register of Historic Places. While the new venue would also host vaudeville performances, it was built to accommodate stage productions and motion picture screenings. It underwent major renovations in 1924 and continued to operate for years, moving mainly to showings of motion pictures, but ultimately closed in 1978. In the years following, there were failed attempts to convert the theater into a rock concert hall and it had a brief stint as a special events space. For the past several years, it has served as a place of worship by its current owners. The venue has undergone several upgrades by its previous owners, Dougherty said, including updates to the building's lighting, heating and sound system to ensure they follow modern codes. The theater's iconic marquee from 1924, which was damaged during a storm in 2020, was also recreated in recent years. Despite this, though, Dougherty said the building still maintains much of its historical architecture and vibrant design details. "It's got original marble. It has the concession bar just as it was built," she said. "It's has these beautiful gold, ornate ceilings and columns. Literally, you walk in and walk back in time. But it's been updated enough to be able to really support what anyone wants to use it for." Situated in the Blackwell Street Historic District, she said the Baker Theater is also protected by Dover's Historic Preservation Commission. Because the commission is responsible for reviewing proposed alterations to historic structures, like the Baker Theater, she said it's likely that someone wouldn't be permitted to make any major changes to the building. Dougherty also noted that if the next owner intends on using the space as a venue for the arts, they could be eligible for grant opportunities through the state to help them with improvement projects. In addition to the Baker Theater, the sale of the property includes five one-bedroom apartments and a vacant retail space, which was previously used as a restaurant. "What a gift that it kept the Baker name," Dougherty said. "I feel like its this historic icon that can draw so much from all over. It's absolutely a jewel of Dover." Maddie McGay is the real estate reporter for and The Record, covering all things worth celebrating about living in North Jersey. Find her on Instagram @maddiemcgay, on X @maddiemcgayy, and sign up for her North Jersey Living newsletter. Do you have a tip, trend or terrific house she should know about? Email her at MMcGay@ This article originally appeared on Baker Theater in Dover NJ listed for sale in Morris County Solve the daily Crossword
Yahoo
23 minutes ago
- Yahoo
[Latest] Global Lenacapavir Injection Market Size/Share Worth USD 5.68 Billion by 2034 at a 5.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Lenacapavir Injection Market size & share revenue was valued at approximately USD 3.5 Billion in 2024 and is expected to reach USD 3.66 Billion in 2025 and is expected to reach around USD 5.68 Billion by 2034, at a CAGR of 5.1% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Gilead Sciences, Dr. Reddy's Laboratories, Hetero, Emcure Pharmaceuticals, Eva Pharma, Ferozsons Laboratories, Mylan (Viatris), ViiV Healthcare, Janssen Pharmaceuticals (Johnson & Johnson), Merck & Co. Inc and others. Austin, TX, USA, July 30, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled 'Lenacapavir Injection Market Size, Trends and Insights By Indication (HIV Treatment, Pre-Exposure Prophylaxis (PrEP)), By Formulation (Injectable, Oral Tablets), By Distribution Channel (Branded Medicine, Generic Medicine), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' in its research database.'According to the latest research study, the demand of the global Lenacapavir Injection Market size & share was valued at approximately USD 3.5 Billion in 2024 and is expected to reach USD 3.66 Billion in 2025 and is expected to reach a value of around USD 5.68 Billion by 2034, at a compound annual growth rate (CAGR) of about 5.1% during the forecast period 2025 to 2034.' Click Here to Access a Free Sample Report of the Global Lenacapavir Injection Market @ Overview As per the industry experts at CMI, Market participants, such as Gilead Sciences, are concentrating on ultra-long-acting antiretroviral therapies for HIV treatment adherence challenges, with Gilead Sciences focusing on Lenacapavir Injection market. Innovations focus on subcutaneous delivery systems, dosing intervals, and pharmacokinetics. Collaborations with public health and clinical organizations are propelling international approvals and access. There are further combination regimens and formulation innovations targeted at HIV with multidrug resistance. Market expansion occurs in low-income countries with equitable pricing, reinforcing social responsibility and supporting ESG objectives. Responsibly managed corporations fill the gaps for global therapy and preventive health care. Key Trends & Drivers Long-Acting HIV Treatment Demand: The treatment lenacapavir, which is administered biannually, is a game changer for patients who have difficulty adhering to daily oral regimens. Lenacapavir's long acting form decreases adherence-related complications and mitigates pill fatigue while improving overall patient convenience especially in low resource settings. Health systems are adopting long-acting injectables as part of simplified HIV care models. This is most notable in high burden areas where providers seek long-term treatments that preserve viral load suppression during periods of infrequent monitoring. This shifts convenience to the provider, which is currently driving adoption globally. Rising Prevalence of Multidrug-Resistant HIV: The clinical challenge posed by an increasing population of patients suffering from multi-drug resistant HIV infections is effectively met by lenacapavir. Lenacapavir, unlike other traditional antiretroviral therapies, maintains its position as a lifeline for individuals requiring extensive treatment history due to its activity against a wide range of HIV strains. Such resilience increases its applicability for salvage therapy regimens. Its novel action as a capsid inhibitor enables it to plug therapeutic holes left by other drugs. Hence, cases of MDR HIV, particularly in Sub-Saharan Africa and Eastern Europe, are increasing and lenacapavir is demanded as a critical component of resistance management. Request a Customized Copy of the Lenacapavir Injection Market Report @ Regulatory Support and Global Access Programs: Lenacapavir is approved and awarded incentives by the FDA, EMA, and Health Canada as a treatment for HIV due to its unique features and promise. These approvals have expedited regional access. At the same time, Gilead collaborates with PEPFAR, WHO, and the Global Fund to incorporate Lenacapavir into their treatment programs for middle and lower-income countries. Such collaborations enhance access and coverage especially in regions highly affected by HIV. The combination of these actions—regulatory, humanitarian, and commerce—strengthens the global supply strategy for lenacapavir while keeping the commercial strategy seamless. Technological Advancements in Injectable Formulations: New technologies that enable extended release of therapeutics through injections have made it possible for Lenacapavir to maintain therapeutic levels for longer periods. Advances in administering injectable therapeutics have made them easier to submit to put to use in almost all healthcare settings, such as initiated bioavailable, lower Mentors devices, and even autoprinters. These improvements also lessen the workload placed on health facilities. They offer discreet and effective treatment to patients. Reduced clinic appointment attendance caters to both rural and urban areas, improving the healthcare system as a whole. The evolution of injectable technologies strengthens Lenacapavir's formulation strategy, resulting in its dominant position as a next-generation platform. Report Scope Feature of the Report Details Market Size in 2025 USD 3.66 Billion Projected Market Size in 2034 USD 5.68 Billion Market Size in 2024 USD 3.5 Billion CAGR Growth Rate 5.1% CAGR Base Year 2024 Forecast Period 2025-2034 Key Segment By Indication, Formulation, Distribution Channel and Region Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America Buying Options Request tailored purchasing options to fulfil your requirements for research. (A free sample of the Lenacapavir Injection report is available upon request; please contact us for more information.) Our Free Sample Report Consists of the following: Introduction, Overview, and in-depth industry analysis are all included in the 2024 updated report. The COVID-19 Pandemic Outbreak Impact Analysis is included in the package. About 220+ Pages Research Report (Including Recent Research) Provide detailed chapter-by-chapter guidance on the Request. Updated Regional Analysis with a Graphical Representation of Size, Share, and Trends for the Year 2025 Includes Tables and figures have been updated. The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis Custom Market Insights (CMI) research methodology (Please note that the sample of the Lenacapavir Injection report has been modified to include the COVID-19 impact study prior to delivery.) Request a Customized Copy of the Lenacapavir Injection Market Report @ SWOT Analysis Strengths: Lenacapavir offers a groundbreaking, long-acting antiretroviral solution, allowing biannual dosing which significantly improves patient compliance compared to daily oral therapies. Its novel capsid inhibitor mechanism targets both treatment-naïve and drug-resistant HIV strains. Backed by strong clinical trial results and regulatory approvals like the FDA and EMA, it provides pharmaceutical firms with first-mover advantages and intellectual property exclusivity that strengthens market leadership in HIV care. Weaknesses: Increased cold-chain logistics of the injectable form in low resource areas add to already heightened innovative manufacturing costs. Further, the need for provider administration may turn away needle averse patients which adds to an already strained healthcare infrastructure. Adoption by clinicians, particularly in conservative markets, is stifled by the conservative reimbursement policies from insurers, mainly due to the lack of long-term safety data of this new class of therapeutics. Opportunities: As the global prevalence of HIV increases, lenacapavir takes the role of addressing the enduring adherence challenges. Further, expansion through co-formulation opens up the potential for additional wide-ranging clinical studies for preventive (PrEP) therapies. Working with global health organizations, strategic relationships with low income countries can help penetrate poorly served markets. Inclusion into national HIV programs increases public sector uptake while amplifying global impact. Threats: Lenacapavir is facing competing long-acting antiretroviral agents such as cabotegravir and rilpivirine-based therapies. The erosion of profit margins due to expiring patents, the development of biosimilars and competition from global procurement agencies may increase costs. Emerging issues related to safety or viral resistance can impact clinical confidence significantly. Revenue growth potential from key emerging markets may be restricted by regulatory delays, which in turn slows down market entry. Request a Customized Copy of the Lenacapavir Injection Market Report @ Key questions answered in this report: What is the size of the Lenacapavir Injection market and what is its expected growth rate? What are the primary driving factors that push the Lenacapavir Injection market forward? What are the Lenacapavir Injection Industry's top companies? What are the different categories that the Lenacapavir Injection Market caters to? What will be the fastest-growing segment or region? In the value chain, what role do essential players play? What is the procedure for getting a free copy of the Lenacapavir Injection market sample report and company profiles? Key Offerings: Market Share, Size & Forecast by Revenue | 2025−2034 Market Dynamics – Growth Drivers, Restraints, Investment Opportunities, and Leading Trends Market Segmentation – A detailed analysis by Types of Services, by End-User Services, and by regions Competitive Landscape – Top Key Vendors and Other Prominent Vendors Buy this Premium Lenacapavir Injection Research Report | Fast Delivery Available - [220+ Pages] @ Regional Perspective The Lenacapavir Injection Market can be divided across different regions such as North America, Europe, Asia-Pacific, and LAMEA. This is a cursory overview of each region: North America: The Region's market for lenacapavir is led by the U.S. due to early regulatory approvals, infrastructure, and a high rate of HIV prevalence. in addition to reimbursement and innovative clinical programs, there are also major research institutions in the region. uptake is higher than average among hard-to-treat patient groups and during public health programs. there still remains a significant opportunity for PRP and other injectable treatment options. therefore, prep commercialization continues to be innovative in North America. Europe: Europe also represents a large market opportunity for lenacapavir due to its ema approval and geographical access programs. other health systems have started integrating the drug into their HIV treatment framework. countries such as Germany, France, and the UK are early adopters along with support for injectable based regimens. the European region also provides a shift towards sustainable healthcare delivery in the management of infectious diseases. Asia-Pacific: The region comprises countries with a high HIV burden, such as Thailand, India, and China. It is an emerging growth area. Some markets are still awaiting regulatory approval, but aid-funded rollouts and international subsidy programs are facilitating access. The region's population size, coupled with rising healthcare spending, makes it ready for long-acting antiretroviral therapies. The region also poses challenges of affordability and cold-chain maintenance. If these are solved, particularly through local licensing and manufacturing, the next five years could witness exponential growth of the region. LAMEA: The LAMEA Lenacapavir market is marked by the expanding need for long-acting treatments in healthcare access-challenged regions. Brazil, Argentina, and Chile are leading as they have more advanced public health systems. While regulations are still being updated, NGOs and global donors are providing critical early access distribution. Access is especially acute for underresourced groups, and the region is seen as a prime candidate for future generic penetration. These will also help generate broader market acceptance through strategic partnerships and government tenders. Request a Customized Copy of the Lenacapavir Injection Market Report @ (We customized your report to meet your specific research requirements. Inquire with our sales team about customizing your report.) Still, Looking for More Information? Do OR Want Data for Inclusion in magazines, case studies, research papers, or Media? Email Directly Here with Detail Information: support@ Browse the full 'Lenacapavir Injection Market Size, Trends and Insights By Indication (HIV Treatment, Pre-Exposure Prophylaxis (PrEP)), By Formulation (Injectable, Oral Tablets), By Distribution Channel (Branded Medicine, Generic Medicine), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' Report at of the prominent players in the Lenacapavir Injection Market: Gilead Sciences Reddy's Laboratories Hetero Emcure Pharmaceuticals Eva Pharma Ferozsons Laboratories Mylan (Viatris) ViiV Healthcare Janssen Pharmaceuticals (Johnson & Johnson) Merck & Co. Inc Others Click Here to Access a Free Sample Report of the Global Lenacapavir Injection Market @ Spectacular Deals Comprehensive coverage Maximum number of market tables and figures The subscription-based option is offered. Best price guarantee Free 35% or 60 hours of customization. Free post-sale service assistance. 25% discount on your next purchase. Service guarantees are available. Personalized market brief by author. Browse More Related Reports: Pharmaceutical Metal Detector Market: Pharmaceutical Metal Detector Market Size, Trends and Insights By Technology (Magnetic Field Detectors, Multi-frequency Detectors, X-Ray Inspection with Metal Detectors), By Application (Quality Control, Contaminant Detection, Packaging, Compliance), By End-user (Pharmaceutical Companies, Contract Development and Manufacturing Organizations (CDMOs), Biopharmaceutical Companies), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Deep Eutectic Solvents Market: Deep Eutectic Solvents Market Size, Trends and Insights By Product (Organic Salts + Metal Salts, Organic Salts + Metal Hydrates, Organic Salts + Hydrogen Bond Donor, Metal Chlorides + Hydrogen Bond Donor), By End-use (Pharmaceuticals & Healthcare, Food & Beverages Processing, Cosmetics & Personal Care, Chemical & Materials Industry), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025-2034 Medical Equipment Calibration Services Market: Medical Equipment Calibration Services Market Size, Trends and Insights By Service (In-house, Third-party Services, Original Equipment Manufacturers (OEMs)), By End-use (Hospitals, Clinical Laboratories), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 North America Oral Care Market: North America Oral Care Market Size, Trends and Insights By Product Type (Toothbrush, Manual, Electric (Rechargeable), Battery-powered (Non-rechargeable), Others, Toothpaste, Gel, Polish, Paste, Powder, Mouthwash/Rinse, Medicated, Non-medicated, Denture Products, Cleaners, Fixatives, Floss, Others, Dental Accessories, Cosmetic Whitening Products, Fresh Breath Dental Chewing Gum, Tongue Scrapers, Fresh Breath Strips, Others, Oral Irrigators, Mouth Freshener Sprays), By Age Group (Kids, Adults, Geriatric), By Type (Countertop, Cordless), By Application (Home, Dentistry), By Sales Channel (Hypermarkets/Supermarkets, Specialty Stores, Drug Stores &Pharmacies, Convenience Stores, Online Sales Channel), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 AI in Synthetic Biology Market: AI in Synthetic Biology Market Size, Trends and Insights By Technology (Gene Synthesis, Genome Editing, Synthetic Biology Tools, Bioinformatics), By Application (Healthcare & Medicine, Agricultural Biotechnology, Industrial Biotechnology, Environmental Biotechnology), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Alzheimer's Drug Market: Alzheimer's Drug Market Size, Trends and Insights By Type of Drug (Disease-Modifying Therapies (DMTs), Symptomatic Therapies), By Application (Amyloid-Targeting Agents, Tau-Targeting Agents, Cholinesterase Inhibitors, NMDA Antagonists, Other Agents), By End User (Hospitals, Clinics, Home Care Settings), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Japan Cell Cancer Vaccine Market: Japan Cell Cancer Vaccine Market Size, Trends and Insights By Vaccine Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines, Oncolytic Viruses), By Indication (Prostate Cancer, Cervical Cancer), By Technology (Peptide-based Vaccines, Vector-based Vaccines, DNA/RNA-based Vaccines), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 mRNA Cancer Vaccine Market: mRNA Cancer Vaccine Market Size, Trends and Insights By Cancer Type (Melanoma, Lung Cancer (NSCLC), Prostate Cancer, Pancreatic Cancer, Colorectal Cancer), By Application/Use Case (Therapeutic Cancer Vaccines, Preventive/Prophylactic Cancer Vaccines), By Delivery Mechanism (Lipid Nanoparticles (LNPs), Polymer-Based Carriers, Electroporation), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 The Lenacapavir Injection Market is segmented as follows: By Indication HIV Treatment Pre-Exposure Prophylaxis (PrEP) By Formulation Injectable Oral Tablets By Distribution Channel Branded Medicine Generic Medicine Click Here to Get a Free Sample Report of the Global Lenacapavir Injection Market @ Regional Coverage: North America U.S. Canada Mexico Rest of North America Europe Germany France U.K. Russia Italy Spain Netherlands Rest of Europe Asia Pacific China Japan India New Zealand Australia South Korea Taiwan Rest of Asia Pacific The Middle East & Africa Saudi Arabia UAE Egypt Kuwait South Africa Rest of the Middle East & Africa Latin America Brazil Argentina Rest of Latin America This Lenacapavir Injection Market Research/Analysis Report Contains Answers to the following Questions. Which Trends Are Causing These Developments? Who Are the Global Key Players in This Lenacapavir Injection Market? What are Their Company Profile, Product Information, and Contact Information? What Was the Global Market Status of the Lenacapavir Injection Market? What Was the Capacity, Production Value, Cost and PROFIT of the Lenacapavir Injection Market? What Is the Current Market Status of the Lenacapavir Injection Industry? What's Market Competition in This Industry, Both Company and Country Wise? What's Market Analysis of Lenacapavir Injection Market by Considering Applications and Types? What Are Projections of the Global Lenacapavir Injection Industry Considering Capacity, Production and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply and Consumption? What about imports and exports? What Is Lenacapavir Injection Market Chain Analysis by Upstream Raw Materials and Downstream Industry? What Is the Economic Impact On Lenacapavir Injection Industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends? What Are Market Dynamics of Lenacapavir Injection Market? What Are Challenges and Opportunities? What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for Lenacapavir Injection Industry? Click Here to Access a Free Sample Report of the Global Lenacapavir Injection Market @ Reasons to Purchase Lenacapavir Injection Market Report Lenacapavir Injection Market Report provides qualitative and quantitative analysis of the market based on segmentation involving economic and non-economic factors. Lenacapavir Injection Market report outlines market value (USD) data for each segment and sub-segment. This report indicates the region and segment expected to witness the fastest growth and dominate the market. Lenacapavir Injection Market Analysis by geography highlights the consumption of the product/service in the region and indicates the factors affecting the market within each region. The competitive landscape incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled. Extensive company profiles comprising company overview, company insights, product benchmarking, and SWOT analysis for the major market players. The Industry's current and future market outlook concerning recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging and developed regions. Lenacapavir Injection Market Includes in-depth market analysis from various perspectives through Porter's five forces analysis and provides insight into the market through Value Chain. Reasons for the Research Report The study provides a thorough overview of the global Lenacapavir Injection market. Compare your performance to that of the market as a whole. Aim to maintain competitiveness while innovations from established key players fuel market growth. Buy this Premium Lenacapavir Injection Research Report | Fast Delivery Available - [220+ Pages] @ What does the report include? Drivers, restrictions, and opportunities are among the qualitative elements covered in the worldwide Lenacapavir Injection market analysis. The competitive environment of current and potential participants in the Lenacapavir Injection market is covered in the report, as well as those companies' strategic product development ambitions. According to the component, application, and industry vertical, this study analyzes the market qualitatively and quantitatively. Additionally, the report offers comparable data for the important regions. For each segment mentioned above, actual market sizes and forecasts have been given. Who should buy this report? Participants and stakeholders worldwide Lenacapavir Injection market should find this report useful. The research will be useful to all market participants in the Lenacapavir Injection industry. Managers in the Lenacapavir Injection sector are interested in publishing up-to-date and projected data about the worldwide Lenacapavir Injection market. Governmental agencies, regulatory bodies, decision-makers, and organizations want to invest in Lenacapavir Injection products' market trends. Market insights are sought for by analysts, researchers, educators, strategy managers, and government organizations to develop plans. Request a Customized Copy of the Lenacapavir Injection Market Report @ About Custom Market Insights: Custom Market Insights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains. CMI provides a one-stop solution for data collection to investment advice. The expert analysis of our company digs out essential factors that help to understand the significance and impact of market dynamics. The professional experts apply clients inside on the aspects such as strategies for future estimation fall, forecasting or opportunity to grow, and consumer survey. Follow Us: LinkedIn | Twitter | Facebook | YouTube Contact Us: Joel John CMI Consulting LLC 1333, 701 Tillery Street Unit 12, Austin, TX, Travis, US, 78702 USA: +1 737-734-2707 India: +91 20 46022736 Email: support@ Web: Blog: Blog: Blog: Blog: Buy this Premium Lenacapavir Injection Research Report | Fast Delivery Available - [220+ Pages] @
Yahoo
23 minutes ago
- Yahoo
Uber Technologies Stock: Is Wall Street Bullish or Bearish?
San Francisco, California-based Uber Technologies, Inc. (UBER) provides a platform that allows users to access transportation and food ordering services. With a market cap of $189.5 billion, Uber operates the world's largest mobility platform with its operations spanning approximately 70 countries and over 10,000 cities across the globe. The mobility giant has significantly outperformed the broader market over the past year. Uber has soared 44.4% on a YTD basis and 36.6% over the past 52 weeks, outpacing the S&P 500 Index's ($SPX) 8.3% gains in 2025 and 16.6% surge over the past year. More News from Barchart Here's What Happened the Last Time Novo Nordisk Stock Was This Oversold Tesla Just Signed a Chip Supply Deal with Samsung. What Does That Mean for TSLA Stock? Earnings Will Be 'Worse Than Expected' for UnitedHealth. How Should You Play UNH Stock Here? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Narrowing the focus, UBER has also outpaced the sector-focused Technology Select Sector SPDR Fund's (XLK) 13.6% gains on a YTD basis, and 22.7% returns over the past 52 weeks. Uber Technologies' stock prices dropped 2.5% following the release of its mixed Q1 results on May 7. Continuing its solid momentum, the number of trips through Uber's platform increased 18% year-over-year to 3 billion, which was primarily supported by an increase in monthly active users. Meanwhile, its revenues increased nearly 17% on a constant currency basis. However, due to a stronger dollar during the quarter, its revenues increased by 14% on a reported basis to $11.5 billion, missing the consensus estimates by a small margin. Its adjusted EBITDA increased by an even more impressive 35% year-over-year to $1.9 billion, and its EPS of $0.83 beat the Street's expectations by 62.8%. For the full fiscal 2025, ending in December, analysts expect Uber to deliver an EPS of $2.90, marking a 36.4% decline year-over-year. However, the company has a solid earnings surprise history. It has surpassed the Street's bottom-line expectations in each of the past four quarters by a large margin. Uber has a consensus 'Strong Buy' rating overall. Of the 47 analysts covering the stock, opinions include 32 'Strong Buys,' five 'Moderate Buys,' and 10 'Holds.' This configuration is slightly less bullish than two months ago, when 34 analysts gave 'Strong Buy' recommendations. On Jul. 29, Stifel analyst Mark Kelley reiterated a 'Buy' rating on Uber and raised the price target to $117. Its mean price target of $101.58 suggests a 16.6% upside from current price levels, while the Street high target of $120 represents a 37.8% premium. On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
